Recombinant Human Tumor Susceptibility Gene 101
|Amount :||10 µg|
|Purification :||Greater than 90% as determined by SDS-PAGE.|
|Content :||TSG101 protein solution (0.5mg/ml) containing 20mM Tris-HCl pH-8, 1mM DTT and 10% glycerol.|
|Storage condition :||Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.|
|AA sequence :||MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWGSMAVS ESQLKKMVSK YKYRDLTVRE TVNVITLYKD LKPVLDSYVF NDGSSRELMN LTGTIPVPYR GNTYNIPICL WLLDTYPYNP PICFVKPTSS MTIKTGKHVD ANGKIYLPYL HEWKHPQSDL LGLIQVMIVV FGDEPPVFSR P.|
|Alternative Name :||TSG10, VPS23, TSG101, ESCRT-I complex subunit TSG101, Tumor susceptibility gene 101 protein.|
Source : Escherichia Coli. TSG101 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 181 amino acids (1-145 a.a.) and having a molecular mass of 20.7 kDa. TSG101 protein is fused to a 36 amino acid His-Tag at N-terminus and purified by standard chromatography. TSG101 is a member of apparently inactive homologs of ubiquitin-conjugating enzymes. TSG101 contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. TSG101 is involved in cell growth and differentiation and acts as a negative growth regulator. TSG101 in vitro steady-state expression is important for maintenance of genomic stability and cell cycle regulation. TSG101 mutations and alternative splicing occur in high rate in breast cancer and implicate that defects occur during breast cancer tumorigenesis and/or progression. TSG101 is a factor of the ESCRT-I complex, a monitor of vesicular trafficking process. TSG101 binds to ubiquitinated cargo proteins and is needed for the sorting of endocytic ubiquitinated cargos into multivesicular bodies. TSG101 is needed for completion of cytokinesis and is involved in cell growth and differentiation.